Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements | Zendy

Ilaria Tanasi | Zendy; Ibrahima Ba | Zendy; Nicolas Sirvent | Zendy; Thorsten Braun | Zendy; Wendy Cuccuini | Zendy; Paola Ballerini | Zendy; Nicolas Duployez | Zendy; Aline Schmidt | Zendy; Jérôme Tamburini | Zendy; Sébastien Maury | Zendy; Éric Doré | Zendy; Chantal Himberlin | Zendy; Cédric Duclos | Zendy; Patrice Chevallier | Zendy; Philippe Rousselot | Zendy; Massimiliano Bonifacio | Zendy; Hélène Cavé | Zendy; André Baruchel | Zendy; Hervé Dombret | Zendy; Jean Soulier | Zendy; Judith LandmanParker | Zendy; Nicolas Boissel | Zendy; Emmanuelle Clappier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

Author(s) -

Ilaria Tanasi,

Ibrahima Ba,

Nicolas Sirvent,

Thorsten Braun,

Wendy Cuccuini,

Paola Ballerini,

Nicolas Duployez,

Aline Schmidt,

Jérôme Tamburini,

Sébastien Maury,

Éric Doré,

Chantal Himberlin,

Cédric Duclos,

Patrice Chevallier,

Philippe Rousselot,

Massimiliano Bonifacio,

Hélène Cavé,

André Baruchel,

Hervé Dombret,

Jean Soulier,

Judith LandmanParker,

Nicolas Boissel,

Emmanuelle Clappier

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019001244

Subject(s) - lymphoblastic leukemia , tyrosine kinase , medicine , cd135 , abl , cancer research , tyrosine kinase inhibitor , acute lymphocytic leukemia , leukemia , cancer , receptor

Tanasi et al present a prospective strategy for identifying patients with Philadelphia-like acute lymphoblastic leukemia, demonstrating the efficacy of early introduction of tyrosine kinase inhibitors in improving outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research